Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

M. Pribyl, S. Hubackova, A. Moudra, M. Vancurova, H. Polackova, T. Stopka, A. Jonasova, R. Bokorova, O. Fuchs, J. Stritesky, B. Salovska, J. Bartek, Z. Hodny

. 2020 ; 14 (10) : 2403-2419. [pub] 20200811

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc21026538

Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging, autoinflammation and autoimmunity are crucial features of disease progression, concordant with promoting growth of malignant clones and accumulation of mutations. Suprabasin (SBSN), a recently proposed proto-oncogene of unknown function, physiologically expressed in stratified epithelia, is associated with poor prognosis of several human malignancies. Here, we showed that SBSN is expressed in the BM by myeloid cell subpopulations, including myeloid-derived suppressor cells, and is secreted into BM plasma and peripheral blood of MDS patients. The highest expression of SBSN was present in a patient group with poor prognosis. SBSN levels in the BM correlated positively with blast percentage and negatively with CCL2 chemokine levels and lymphocyte count. In vitro treatment of leukemic cells with interferon-gamma and demethylating agent 5-azacytidine (5-AC) induced SBSN expression. This indicated that aberrant cytokine levels in the BM and epigenetic landscape modifications in MDS patients may underlie ectopic expression of SBSN. Our findings suggest SBSN as a candidate biomarker of high-risk MDS with a possible role in disease progression and therapy resistance.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026538
003      
CZ-PrNML
005      
20250506112256.0
007      
ta
008      
211013s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/1878-0261.12768 $2 doi
035    __
$a (PubMed)32696549
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pribyl, Miroslav $u Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
245    10
$a Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes / $c M. Pribyl, S. Hubackova, A. Moudra, M. Vancurova, H. Polackova, T. Stopka, A. Jonasova, R. Bokorova, O. Fuchs, J. Stritesky, B. Salovska, J. Bartek, Z. Hodny
520    9_
$a Myelodysplastic syndromes (MDS) are preleukemic disorders characterized by clonal growth of mutant hematopoietic stem and progenitor cells. MDS are associated with proinflammatory signaling, dysregulated immune response, and cell death in the bone marrow (BM). Aging, autoinflammation and autoimmunity are crucial features of disease progression, concordant with promoting growth of malignant clones and accumulation of mutations. Suprabasin (SBSN), a recently proposed proto-oncogene of unknown function, physiologically expressed in stratified epithelia, is associated with poor prognosis of several human malignancies. Here, we showed that SBSN is expressed in the BM by myeloid cell subpopulations, including myeloid-derived suppressor cells, and is secreted into BM plasma and peripheral blood of MDS patients. The highest expression of SBSN was present in a patient group with poor prognosis. SBSN levels in the BM correlated positively with blast percentage and negatively with CCL2 chemokine levels and lymphocyte count. In vitro treatment of leukemic cells with interferon-gamma and demethylating agent 5-azacytidine (5-AC) induced SBSN expression. This indicated that aberrant cytokine levels in the BM and epigenetic landscape modifications in MDS patients may underlie ectopic expression of SBSN. Our findings suggest SBSN as a candidate biomarker of high-risk MDS with a possible role in disease progression and therapy resistance.
650    _2
$a diferenciační antigeny $x krev $x genetika $x metabolismus $7 D000943
650    _2
$a azacytidin $x farmakologie $7 D001374
650    _2
$a biologické markery $x krev $x metabolismus $7 D015415
650    _2
$a kostní dřeň $x metabolismus $7 D001853
650    _2
$a kompartmentace buňky $x účinky léků $7 D002451
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a chemokin CCL2 $x metabolismus $7 D018932
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a lidé $7 D006801
650    _2
$a interferon gama $x farmakologie $7 D007371
650    _2
$a leukocyty mononukleární $x metabolismus $7 D007963
650    _2
$a počet lymfocytů $7 D018655
650    _2
$a myelodysplastické syndromy $x krev $x metabolismus $7 D009190
650    _2
$a myeloidní buňky $x účinky léků $x metabolismus $7 D022423
650    _2
$a nádorové proteiny $x krev $x genetika $x metabolismus $7 D009363
650    _2
$a prognóza $7 D011379
650    _2
$a messenger RNA $x genetika $x metabolismus $7 D012333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hubackova, Sona $u Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic $u Molecular Therapy of Cancer Group, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prague, Czech Republic
700    1_
$a Moudra, Alena $u Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Vancurova, Marketa $u Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Polackova, Helena $u 1st Department of Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Stopka, Tomas $u 1st Department of Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic $u Group of Mechanisms Involved in Remodeling of Chromatin Structure During Cell Fate Decisions, BIOCEV, Prague, Czech Republic
700    1_
$a Jonasova, Anna $u 1st Department of Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Bokorova, Radka $u Department of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Fuchs, Ota $u Department of Genomics, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Stritesky, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Salovska, Barbora $u Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Bártek, Jiří, $d 1953- $u Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic $u Danish Cancer Society Research Center, Copenhagen, Denmark $u Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden $7 xx0046271
700    1_
$a Hodny, Zdenek $u Department of Genome Integrity, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic
773    0_
$w MED00167281 $t Molecular oncology $x 1878-0261 $g Roč. 14, č. 10 (2020), s. 2403-2419
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32696549 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20250506112255 $b ABA008
999    __
$a ok $b bmc $g 1715305 $s 1147045
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 14 $c 10 $d 2403-2419 $e 20200811 $i 1878-0261 $m Molecular oncology $n Mol Oncol $x MED00167281
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options